EUVIMEDEUVIMED entdecken
Übersichtsarbeit

BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy

Anna Płotka, Krzysztof Lewandowski

Acta Haematologica · 2022 · 145 (2) · 122-131

DOI: 10.1159/000519782 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Haematologica, online erschienen am 24.11.2021. Verfasst von Anna Płotka und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznań, Poland. Hauptthemen laut MEDLINE: Molecular Targeted Therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 63 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: BCR/ABL1-like acute lymphoblastic leukemia is a newly recognized high-risk subtype of ALL, characterized by the presence of genetic alterations activating kinase and cytokine receptor signaling. This subtype is associated with inferior outcomes, compared to other B-cell precursor ALL. Summary: The recognition of BCR/ABL1-like ALL is challenging due to the complexity of underlying genetic alterations. Rearrangements of CRLF2 are the most frequent alteration in BCR/ABL1-like ALL and can be identified by flow cytometry. The identification of BCR/ABL1-like ALL can be achieved with stepwise algorithms or broad-based testing. The main goal of the diagnostic analysis is to detect the underlying genetic alterations, which are critical for the diagnosis and targeted therapy. Key Messages: The aim of the manuscript is to review the available data on BCR/ABL1-like ALL characteristics, diagnostic algorithms, and novel, molecularly targeted therapeutic options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Targeted TherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaFusion Proteins, bcr-ablGene RearrangementHumansMutation

Stichwörter der Autor:innen

BCR/ABL1-like acute lymphoblastic leukemiaCytogeneticsImmunophenotypeMolecular characteristicMolecular-targeted therapy

Substanzen

Fusion Proteins, bcr-abl

Autor:innen und Institutionen

  • Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznań, Poland.

Zitieren

APA

Płotka, A., & Lewandowski, K. (2022). BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy. Acta Haematologica, 145(2), 122-131. https://doi.org/10.1159/000519782

Vancouver

Płotka A, Lewandowski K. BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy. Acta Haematologica. 2022;145(2):122-131. doi:10.1159/000519782

BibTeX
@article{Potka2022,
  author = {Płotka, Anna and Lewandowski, Krzysztof},
  title = {BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy},
  journal = {Acta Haematologica},
  year = {2022},
  volume = {145},
  number = {2},
  pages = {122--131},
  doi = {10.1159/000519782}
}
Kostenlos starten →